Alisha Kumar, MD
Ophthalmology · Cincinnati, OHNPI 1902148745
Payments from drug & device makers
Across 192 payments — averaging $41.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ivantis, Inc$3K
- AbbVie$1K
- Alcon$755
- Aerie Pharmaceuticals, Inc.$522
- Regeneron Healthcare Solutions, Inc.$354
- Novartis$282
- plus $1K from 21 others
What the payments were for
- Consulting fees$3,00038%
- Food & beverage$4,96762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ivantis, Inc | 11 | $3,293 |
| AbbVie(2 entities) | 52 | $1,352 |
| Alcon | 27 | $755 |
| Aerie Pharmaceuticals, Inc. | 16 | $522 |
| Regeneron Healthcare Solutions, Inc. | 13 | $354 |
| Novartis | 18 | $282 |
| Sight Sciences, Inc. | 3 | $229 |
| Bausch & Lomb Americas Inc. | 11 | $223 |
| Vifor Pharma, Inc. | 1 | $125 |
| Apellis Pharmaceuticals, Inc. | 5 | $110 |
| Alimera Sciences, Inc. | 5 | $99 |
| Biotissue Holdings Inc. | 3 | $83 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $83 |
| Astellas Pharma US Inc | 3 | $78 |
| Tarsus Pharmaceuticals, Inc. | 2 | $49 |
| Thea Pharma Inc. | 2 | $42 |
| Harrow Eye, LLC | 2 | $41 |
| Genentech USA, Inc. | 2 | $38 |
| Amgen(2 entities) | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Kala Pharmaceuticals, Inc. | 2 | $29 |
| Eyepoint US, Inc. | 1 | $26 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Oyster Point Pharma, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| NEW World Medical,inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$3,250
- Rhopressa$352
- Rocklatan$352
- XEN GLAUCOMA TREATMENT SYSTEM$228
- Veltassa$125
- DURYSTA$118
- OMNI(R) SURGICAL SYSTEM (US)$115
How this compares
$7,967 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 149 | $77,338 |
| RocklatanNetarsudil Mesylat/Latanoprost | 71 | $46,894 |
| LumiganBimatoprost | 102 | $44,343 |
| Prednisolone Acetate | 874 | $37,067 |
| Alphagan PBrimonidine Tartrate | 44 | $22,002 |
| Brimonidine Tartrate | 1,045 | $20,459 |
| Timolol MaleateTimolol Maleate/Pf | 48 | $18,033 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 59 | $16,726 |
| MoxifloxacinMoxifloxacin Hcl | 484 | $16,663 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $13,725 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,006 | $13,292 |
| Latanoprost | 1,640 | $13,229 |
| Loteprednol Etabonate | 59 | $12,834 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 88 | $12,666 |
| Brinzolamide | 43 | $9,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $522 | $124,232220 claims |
| AbbVieLumigan, Alphagan P, Combigan | $1,352 | $80,070188 claims |
| AlconSimbrinza | $755 | $16,72659 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $83 | $12,83459 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $223 | $8,51419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cincinnati
- Daniel MillerCincinnati$2.3M
- Michael SnyderCincinnati$1.3M
- Christopher RiemannCincinnati$985K
- Robert SiskCincinnati$831K
- Anup KhatanaCincinnati$794K
- Robert OsherCincinnati$720K
- Haroon ChaudhryCincinnati$708K
- Christopher DevineCincinnati$623K
- Robert BenzaCincinnati$224K
- Linda GreffCincinnati$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.